» Articles » PMID: 39866330

Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy

Overview
Journal ACG Case Rep J
Date 2025 Jan 27
PMID 39866330
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel immunotherapy for the treatment of refractory malignancies. While various complications have been described previously, sclerosing cholangitis has not been reported. We report the first description of sclerosing cholangitis secondary to Tecartus CAR-T therapy in a 67-year-old man with refractory stage IV mantle cell lymphoma. As CAR-T therapy becomes increasingly used in clinical practice, it is critical to recognize potential hepatobiliary complications. Further research is needed to facilitate early diagnosis and to develop effective treatment strategies for managing these rare but severe complications.

References
1.
Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

2.
Ludwig D, Anderson M, Itani M, Sharbidre K, Lalwani N, Paspulati R . Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis. Abdom Radiol (NY). 2022; 48(1):151-165. PMC: 9116710. DOI: 10.1007/s00261-022-03551-z. View

3.
Lamers C, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C . Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013; 21(4):904-12. PMC: 5189272. DOI: 10.1038/mt.2013.17. View

4.
Zhang Y, Li Y, Cao W, Wang F, Xie X, Li Y . Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity". Front Immunol. 2022; 12:799206. PMC: 8716389. DOI: 10.3389/fimmu.2021.799206. View

5.
Cappell K, Kochenderfer J . Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023; 20(6):359-371. PMC: 10100620. DOI: 10.1038/s41571-023-00754-1. View